KOBAYASHI PHARMACEUTICAL  CO.,LTD. Logo

KOBAYASHI PHARMACEUTICAL CO.,LTD.

Develops, manufactures, and markets OTC pharmaceuticals, health, and household goods.

4967 | T

Overview

Corporate Details

ISIN(s):
JP3301100008
LEI:
Country:
Japan
Address:
大阪市中央区道修町4丁目4番10号

Description

Kobayashi Pharmaceutical Co., Ltd. is a company engaged in the development, manufacturing, and marketing of a wide range of consumer products. Its core business segments include over-the-counter (OTC) pharmaceuticals, health and personal care items, and household goods. The company's diverse product portfolio features items such as nutritional supplements, deodorizing air fresheners, and disposable body warmers. Kobayashi Pharmaceutical focuses on creating innovative and niche products designed to solve specific, everyday problems for consumers, reflecting its brand slogan, 'You make a wish and we make it happen'.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2024-05-15 08:00
確認書
Japanese 8.1 KB
2024-05-15 08:00
四半期報告書-第107期第1四半期(2024/01/01-2024/03/31)
Japanese 194.1 KB
2024-05-10 09:00
臨時報告書
Japanese 20.0 KB
2024-05-02 08:53
臨時報告書
Japanese 20.4 KB
2024-03-29 08:36
臨時報告書
Japanese 23.7 KB
2024-03-28 07:02
確認書
Japanese 8.2 KB
2024-03-28 07:02
内部統制報告書-第106期(2023/01/01-2023/12/31)
Japanese 22.2 KB
2024-03-28 07:01
有価証券報告書-第106期(2023/01/01-2023/12/31)
Japanese 2.6 MB
2024-01-09 08:00
訂正臨時報告書
Japanese 34.1 KB
2023-11-10 07:34
確認書
Japanese 8.1 KB
2023-11-10 07:34
四半期報告書-第106期第3四半期(2023/07/01-2023/09/30)
Japanese 224.5 KB
2023-11-08 07:00
臨時報告書
Japanese 33.9 KB
2023-10-13 08:00
臨時報告書
Japanese 21.9 KB
2023-08-10 08:01
確認書
Japanese 8.1 KB
2023-08-10 08:01
四半期報告書-第106期第2四半期(2023/04/01-2023/06/30)
Japanese 214.9 KB

Automate Your Workflow. Get a real-time feed of all KOBAYASHI PHARMACEUTICAL CO.,LTD. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for KOBAYASHI PHARMACEUTICAL CO.,LTD.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for KOBAYASHI PHARMACEUTICAL CO.,LTD. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Access Bio, Inc. Logo
Develops and manufactures in vitro diagnostic solutions for infectious diseases.
United States of America
950130
ACHIEVE LIFE SCIENCES, INC. Logo
A late-stage pharmaceutical company developing a treatment for nicotine dependence.
United States of America
ACHV
AC Immune SA Logo
Biopharmaceutical firm developing precision medicine for neurodegenerative diseases.
United States of America
ACIU
Aclaris Therapeutics, Inc. Logo
Clinical-stage biopharmaceutical company developing drugs for immuno-inflammatory diseases.
United States of America
ACRS
Acrivon Therapeutics, Inc. Logo
Clinical-stage biopharma using proteomics to develop precision oncology therapies.
United States of America
ACRV
Acticor Biotech Logo
Develops treatments for thrombotic diseases, focusing on acute ischemic stroke.
France
ALACT
Actinium Pharmaceuticals, Inc. Logo
Clinical-stage company developing targeted radiotherapies for difficult-to-treat cancers.
United States of America
ATNM
ACTUATE THERAPEUTICS, INC. Logo
Clinical-stage biopharma developing therapies for cancers with high unmet needs.
United States of America
ACTU
AcuCort AB Logo
Develops user-friendly drug formulations for severe and acute allergic reactions.
Sweden
ACUC
Acumen Pharmaceuticals, Inc. Logo
Clinical-stage biopharma developing targeted therapies for Alzheimer's disease.
United States of America
ABOS

Report Sent!

Thank you. We will check the data and update it shortly.

Talk to a Data Expert

Have a question? We'll get back to you promptly.